

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pathophysiology

**Manuscript NO:** 65268

**Title:** Cholangiocarcinoma and liver transplantation: What we know so far

**Reviewer's code:** 03845496

**Position:** Editorial Board

**Academic degree:** DPhil

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** Egypt

**Author's Country/Territory:** Iran

**Manuscript submission date:** 2021-03-03

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-05 15:42

**Reviewer performed review:** 2021-03-13 09:21

**Review time:** 7 Days and 17 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

The current review is a narrative review and focuses on Cholangiocarcinoma (CCA), the second most common type of liver cancer, and reports on the CCA classification and progress in treatment. My minor suggestion is as follow It is well known that escape from immune surveillance contributes to the occurrence of tumors and, with the development of precision medicine, immunotherapy serves an important role in tumor treatment. The authors should mentiond the role of the PD-1 inhibitors in increasing the recruitment of immune cells, and that immunotherapy with checkpoint molecule-specific monoclonal antibodies (mAbs) can be effective for CCA treatment